


Ask a doctor about a prescription for IRBESARTAN/HYDROCHLOROTHIAZIDE TEVA 150 MG/12.5 MG FILM-COATED TABLETS
Patient Information Leaflet
Irbesartan/Hydrochlorothiazide Teva 150mg/12.5mg film-coated tablets EFG
irbesartan / hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information:
Irbesartan/Hydrochlorothiazide Teva is a combination of two active substances, irbesartan and hydrochlorothiazide. Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels, causing them to constrict. This results in an increase in blood pressure. Irbesartan prevents angiotensin-II from binding to these receptors, relaxing blood vessels and reducing blood pressure. Hydrochlorothiazide belongs to a group of medicines (called thiazide diuretics) that increase the amount of urine excreted, reducing blood pressure.
The two active substances in Irbesartan/Hydrochlorothiazide Teva work together to achieve a greater reduction in blood pressure than either substance alone.
Irbesartan/Hydrochlorothiazide Teva is used to treat high blood pressure when treatment with irbesartan or hydrochlorothiazide alone does not provide adequate control of blood pressure.
Do not take Irbesartan/Hydrochlorothiazide Teva
Warnings and precautions
Consult your doctor before starting to take Irbesartan/Hydrochlorothiazide Teva and in any of the following cases:
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.
See also the information under the heading “Do not take Irbesartan/Hydrochlorothiazide Teva”.
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor.
Irbesartan/Hydrochlorothiazide Teva is not recommended during pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby (see section Pregnancy).
You must also inform your doctor:
The amount of hydrochlorothiazide in this medicine may cause positive results in doping tests.
Children and adolescents
Irbesartan/Hydrochlorothiazide Teva should not be given to children and adolescents (under 18 years of age).
In case a child swallows several tablets, contact your doctor immediately.
Using Irbesartan/Hydrochlorothiazide Teva with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Your doctor may need to change your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Irbesartan/Hydrochlorothiazide Teva” and “Warnings and precautions”).
Diuretics, such as hydrochlorothiazide contained in Irbesartan/Hydrochlorothiazide Teva, may have an effect on other medicines. You should not take preparations containing lithium together with Irbesartan/Hydrochlorothiazide Teva without the supervision of your doctor.
You may need to have a blood test if you take:
It is also important to inform your doctor if you are taking other medicines to lower your blood pressure, steroids, medicines to treat cancer, painkillers, medicines for arthritis, or cholestyramine or colestipol resins to lower cholesterol in the blood.
Taking Irbesartan/Hydrochlorothiazide Teva with alcohol
Due to the hydrochlorothiazide contained in Irbesartan/Hydrochlorothiazide Teva, if you drink alcohol while taking this medicine, you may have a greater feeling of dizziness when standing up, especially when getting up from a sitting or lying down position.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will normally advise you to stop taking Irbesartan/Hydrochlorothiazide Teva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine to treat your high blood pressure.
Irbesartan/Hydrochlorothiazide Teva is not recommended during pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are going to start or are breastfeeding. Irbesartan/Hydrochlorothiazide Teva is not recommended for use during breastfeeding. Your doctor may decide to prescribe a different treatment if you want to breastfeed, especially if you are breastfeeding a newborn or premature baby.
Driving and using machines
Irbesartan/Hydrochlorothiazide Teva is unlikely to affect your ability to drive or use machines. However, during treatment of high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, consult your doctor before driving or using machines.
Irbesartan/Hydrochlorothiazide Teva contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
Dose
The recommended dose of Irbesartan/Hydrochlorothiazide Teva is one or two tablets a day. In general, your doctor will prescribe Irbesartan/Hydrochlorothiazide Teva when previous treatments you have received for high blood pressure have not provided adequate control of your blood pressure. Your doctor will tell you how to switch from your previous treatment to Irbesartan/Hydrochlorothiazide Teva.
Method of administration
Irbesartan/Hydrochlorothiazide Teva is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g. a glass of water). You can take Irbesartan/Hydrochlorothiazide Teva with or without food. Try to take your daily dose at the same time each day. It is important that you continue to take Irbesartan/Hydrochlorothiazide Teva until your doctor tells you to stop.
The maximum blood pressure-lowering effect should be achieved after 6-8 weeks of treatment.
If you take more Irbesartan/Hydrochlorothiazide Teva than you should
If you accidentally take too many tablets, contact your doctor immediately.
In case of overdose or accidental ingestion, contact the Toxicology Information Service. Telephone 91 562 04 20, or go to the Emergency Department of the nearest hospital.
If you forget to take Irbesartan/Hydrochlorothiazide Teva
If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these effects may be serious and may require medical attention.
Rarely, cases of allergic skin reactions (skin rash, urticaria) have been reported in patients treated with irbesartan, as well as localized swelling in the face, lips, and/or tongue. If you have any of the above symptoms orexperience shortness of breath, stop taking Irbesartan/Hydrochlorothiazide Teva and contact your doctor immediately.
The side effects reported in clinical studies for patients treated with Irbesartan/Hydrochlorothiazide Teva were:
Common side effects(may affect up to 1 in 10 people):
If any of these side effects get serious, talk to your doctor.
Uncommon side effects(may affect up to 1 in 100 people):
If any of these side effects get serious, talk to your doctor.
Some side effects have been reported since the marketing of Irbesartan/Hydrochlorothiazide Teva, but the frequency of these is unknown. The side effects of unknown frequency are: headache, ringing in the ears, cough, altered taste, indigestion, muscle and joint pain, liver function disorders, and kidney failure, high potassium levels in the blood, and allergic reactions such as skin rash, urticaria, swelling of the face, lips, mouth, tongue, or throat. Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been observed.
As with all combinations of two active substances, it cannot be excluded that side effects associated with each of the individual substances may occur.
Side effects associated with irbesartan:
In addition to the side effects described above, the following have also been observed: chest pain, severe allergic reactions (anaphylactic shock), and decreased platelet count (a blood cell essential for blood clotting).
Side effects associated with hydrochlorothiazide in monotherapy are:
Lack of appetite; stomach upset; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); pancreatitis characterized by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; decreased vision or eye pain due to increased pressure [possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or glaucoma]; low white blood cell count, which can lead to frequent infections, fever; decreased platelet count (a blood cell essential for blood clotting), decreased red blood cell count (anaemia) characterized by tiredness, headaches, shortness of breath when exercising, dizziness, and paleness; kidney disease; lung disorders including pneumonia or fluid accumulation in the lungs; increased sensitivity of the skin to the sun; blood vessel inflammation; a skin disease characterized by peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that can appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasms; irregular heartbeat; low blood pressure after changing body position; swelling of the salivary glands; high blood sugar levels; sugar in the urine; increased levels of certain fats in the blood; high uric acid levels in the blood, which can cause gout.
Frequency “not known”: skin and lip cancer (non-melanoma skin cancer).
It is known that side effects associated with hydrochlorothiazide can increase with higher doses of hydrochlorothiazide.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
Irbesartan/Hydrochlorothiazide Teva packaged in PVC/PVdC/Aluminium white opaque blisters: do not store above 30°C.
Irbesartan/Hydrochlorothiazide Teva packaged in aluminium-aluminium blisters: this medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Irbesartan/Hydrochlorothiazide Teva
Each film-coated tablet of Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Tablet core: povidone, pregelatinized starch (maize), poloxamer 188, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica, and magnesium stearate.
Tablet coating for the 150 mg/12.5 mg dose: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), red iron oxide, yellow iron oxide, and black iron oxide.
Appearance of the Product and Package Contents
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg are film-coated tablets, pale red to red in color, and capsule-shaped. One side of the tablet is marked with the number "93" and the other side of the tablet is marked with the number "7238".
Irbesartan/Hydrochlorothiazide is available in the following formats: 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98, and 100 film-coated tablets in non-perforated blisters: packages of 50x1 film-coated tablet in unit-dose blisters and packages of 28 film-coated tablets in non-perforated calendar blisters.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Manufacturer:
Teva Operations Poland Sp.z.o.o
ul. Mogilska 80
31-546 Kraków
Poland
Teva Pharmaceutical Works Private Limited Company
Pallagi út 13
Debrecen H-4042
Hungary
TEVA UK Ltd
Brampton Road
Hampden Park
Eastbourne, East Sussex
BN22 9AG UK
Pharmachemie B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium Teva Pharma Belgium N.V./S.A./A.G Tel: +32 38207373 | Lithuania UAB Teva Baltics Tel: +370 52660203 |
Bulgaria Тева Фарма ЕООД Tel: +359 24899585 | Luxembourg Teva Pharma Belgium N.V./S.A./A.G. Tel: +32 38207373 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007111 | Hungary Teva Gyógyszergyár Zrt. Tel: +36 12886400 |
Denmark Teva Denmark A/S Tel: +45 44985511 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +353 51321740 |
Germany Teva GmbH Tel: +49 73140208 | Netherlands Teva Nederland B.V. Tel: +31 8000228400 |
Estonia UAB Teva Baltics Estonian branch Tel: +372 6610801 | Norway Teva Norway AS Tel: +47 66775590 |
Greece Specifar A.B.E.E. Tel: +30 2118805000 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070 |
Spain Teva Pharma, S.L.U. Tel: +34 913873280 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459300 |
France Teva Santé Tel: +33 155917800 | Portugal Teva Pharma - Produtos Farmacêuticos, Lda Tel: +351 214767550 |
Croatia Pliva Hrvatska d.o.o Tel: +385 13720000 | Romania Teva Pharmaceuticals S.R.L Tel: +40 212306524 |
Ireland Teva Pharmaceuticals Ireland Tel: +353 19127700 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 15890390 |
Iceland Teva Finland Oy Finland Tel: +358 201805900 | Slovakia Teva Pharmaceuticals Slovakia s.r.o. Tel: +421 257267911 |
Italy Teva Italia S.r.l. Tel: +39 028917981 | Finland Teva Finland Oy Tel: +358 201805900 |
Cyprus Specifar A.B.E.E. Greece Tel: +30 2118805000 | Sweden Teva Sweden AB Tel: +46 42121100 |
Latvia UAB Teva Baltics, Latvian branch Tel: +371 67323666 | United Kingdom Teva UK Limited Tel: +44 1977628500 |
Date of Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency (EMA) website http://www.ema.europa.eu/
The average price of IRBESARTAN/HYDROCHLOROTHIAZIDE TEVA 150 MG/12.5 MG FILM-COATED TABLETS in December, 2025 is around 9.65 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IRBESARTAN/HYDROCHLOROTHIAZIDE TEVA 150 MG/12.5 MG FILM-COATED TABLETS – subject to medical assessment and local rules.